$IBIO
iBio, Inc. Stock $ibio

$ibio Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114420418059349 Filed on November 13, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$651.0K	$45.00K	$122.0K
YoY Change	325.49%	-63.11%	238.89%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.393M	$2.871M	$2.500M
YoY Change	31.0%	14.84%	1.21%
% of Gross Profit
Research & Development	$1.273M	$1.124M	$985.0K
YoY Change	28.2%	14.11%	20.12%
% of Gross Profit
Depreciation & Amortization	$364.0K	$360.0K	$338.0K
YoY Change	6.74%	6.51%	4.32%
% of Gross Profit
Operating Expenses	$4.666M	$3.995M	$3.483M
YoY Change	30.34%	14.7%	5.87%
Operating Profit	-$4.015M	-$3.950M	-$3.361M
YoY Change	17.16%	17.52%
Interest Expense	$476.0K	$476.0K	$480.0K
YoY Change	-0.63%	-0.83%	-202.13%
% of Operating Profit
Other Income/Expense, Net	-$455.0K	-$449.0K	-$466.0K
YoY Change	-3.81%	-3.65%	-4760.0%
Pretax Income	-$4.470M	-$4.399M	-$3.830M
YoY Change	14.62%	14.86%	6.09%
Income Tax
% Of Pretax Income
Net Earnings	-$4.469M	-$4.398M	-$3.826M
YoY Change	14.62%	14.95%	25.03%
Net Earnings / Revenue	-686.48%	-9773.33%	-3136.07%
Basic Earnings Per Share
Diluted Earnings Per Share	-$239.1K	-$245.8K	-$416.8K
COMMON SHARES
Basic Shares Outstanding	18.64M shares	18.34M shares	92.82M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.36M	$16.01M	$5.920M
YoY Change	82.78%	170.44%	-70.55%
Cash & Equivalents	$13.36M	$16.01M	$5.916M
Short-Term Investments
Other Short-Term Assets	$396.0K	$206.0K	$210.0K
YoY Change	4.21%	-1.9%	61.54%
Inventory			$0.00
Prepaid Expenses
Receivables	$155.0K	$119.0K	$260.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.97M	$16.34M	$6.380M
YoY Change	78.63%	156.03%	-68.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.81M	$24.98M	$25.27M
YoY Change	-1.89%	-1.14%	-1.22%
Goodwill
YoY Change
Intangibles	$1.498M	$1.554M	$1.757M
YoY Change	-11.99%	-11.55%	-13.15%
Long-Term Investments
YoY Change
Other Assets	$24.00K	$26.00K	$30.00K
YoY Change	-20.0%	-13.33%	0.0%
Total Long-Term Assets	$26.33M	$26.56M	$27.05M
YoY Change	-2.54%	-1.82%	-2.09%
TOTAL ASSETS
Total Short-Term Assets	$13.97M	$16.34M	$6.380M
Total Long-Term Assets	$26.33M	$26.56M	$27.05M
Total Assets	$40.30M	$42.90M	$33.43M
YoY Change	15.68%	28.3%	-30.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$662.0K	$692.0K	$600.0K
YoY Change	-5.43%	15.33%	-38.78%
Accrued Expenses	$1.052M	$1.125M	$1.050M
YoY Change	-6.9%	7.14%	2.94%
Deferred Revenue	$2.526M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$205.0K	$201.0K	$190.0K
YoY Change	7.89%	5.79%	11.76%
Total Short-Term Liabilities	$4.445M	$5.036M	$2.110M
YoY Change	117.47%	138.67%	-2.94%
LONG-TERM LIABILITIES
Long-Term Debt	$24.78M	$24.83M	$25.03M
YoY Change	-0.84%	-0.79%	-0.75%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$24.78M	$24.83M	$25.03M
YoY Change	-0.84%	-0.79%	-0.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.445M	$5.036M	$2.110M
Total Long-Term Liabilities	$24.78M	$24.83M	$25.03M
Total Liabilities	$29.23M	$29.87M	$27.14M
YoY Change	8.12%	10.05%	-0.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$97.10M	-$92.63M
YoY Change
Common Stock	$108.2M	$105.7M
YoY Change	93993.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.08M	$13.03M	$6.290M
YoY Change
Total Liabilities & Shareholders Equity	$40.30M	$42.90M	$33.43M
YoY Change	15.68%	28.32%	-30.48%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$4.469M	-$4.398M	-$3.826M
YoY Change	14.62%	14.95%	25.03%
Depreciation, Depletion And Amortization	$364.0K	$360.0K	$338.0K
YoY Change	6.74%	6.51%	4.32%
Cash From Operating Activities	-$4.670M	-$778.0K	-$3.017M
YoY Change	30.08%	-74.21%	32.73%
INVESTING ACTIVITIES
Capital Expenditures	-$389.0K	$274.0K	$96.00K
YoY Change	94.5%	185.42%	-76.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$389.0K	-$289.0K	-$111.0K
YoY Change	94.5%	160.36%	-81.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$1.350M	$1.000M
YoY Change		35.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.410M	$1.143M	$956.0K
YoY Change	-53.47%	19.56%	-2431.71%
NET CHANGE
Cash From Operating Activities	-4.670M	-$778.0K	-$3.017M
Cash From Investing Activities	-389.0K	-$289.0K	-$111.0K
Cash From Financing Activities	2.410M	$1.143M	$956.0K
Net Change In Cash	-2.649M	$76.00K	-$2.172M
YoY Change	-290.58%	-103.5%	-25.51%
FREE CASH FLOW
Cash From Operating Activities	-$4.670M	-$778.0K	-$3.017M
Capital Expenditures	-$389.0K	$274.0K	$96.00K
Free Cash Flow	-$4.281M	-$1.052M	-$3.113M
YoY Change	26.28%	-66.21%	16.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16010000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15934000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	119000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	75000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	206000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	276000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	16335000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	16285000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24981000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25152000	USD
CY2018Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1554000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1620000	USD
CY2018Q3	us-gaap	Security Deposit SecurityDeposit	26000	USD
CY2018Q2	us-gaap	Security Deposit SecurityDeposit	26000	USD
CY2018Q3	us-gaap	Assets Assets	42896000	USD
CY2018Q2	us-gaap	Assets Assets	43083000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	692000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	790000	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1125000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1048000	USD
CY2018Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	201000	USD
CY2018Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	197000	USD
CY2018Q3	us-gaap	Deferred Revenue DeferredRevenue	3018000	USD
CY2018Q2	us-gaap	Deferred Revenue DeferredRevenue	0	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5036000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2035000	USD
CY2018Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	24832000	USD
CY2018Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	24884000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	29868000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2498000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	3995000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	3483000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3950000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	26919000	USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	16000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	105670000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	104408000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-30000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92626000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88228000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	13031000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	16166000	USD
CY2018Q3	us-gaap	Minority Interest MinorityInterest	-3000	USD
CY2018Q2	us-gaap	Minority Interest MinorityInterest	-2000	USD
CY2018Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13028000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42896000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43083000	USD
CY2018Q3	us-gaap	Revenues Revenues	45000	USD
CY2017Q3	us-gaap	Revenues Revenues	122000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1124000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	985000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2871000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3361000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	476000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	480000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	21000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
CY2018Q3	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	6000	USD
CY2017Q3	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	9000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-449000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-466000	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-4399000	USD
CY2018Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	USD
CY2017Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	USD
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-3827000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4400000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3827000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16164000	USD
CY2018Q3	ibio	Stock Issued During Period Value Common Stock StockIssuedDuringPeriodValueCommonStock	1350000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	159000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	73000	USD
CY2017Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8915000	USD
CY2017Q3	ibio	Stock Issued During Period Value Common Stock StockIssuedDuringPeriodValueCommonStock	1000000	USD
CY2017Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	USD
CY2017Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	205000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3017000	USD
CY2017Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6293000	USD
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	73000	USD
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	205000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	83000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	85000	USD
CY2018Q3	us-gaap	Depreciation Depreciation	360000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	338000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	44000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	85000	USD
CY2018Q3	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	0	USD
CY2017Q3	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	-26000	USD
CY2018Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-70000	USD
CY2017Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-77000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-16000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-78000	USD
CY2018Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	77000	USD
CY2017Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	123000	USD
CY2018Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3018000	USD
CY2017Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	119000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-778000	USD
CY2018Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15000	USD
CY2017Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15000	USD
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	274000	USD
CY2017Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	96000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-289000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-111000	USD
CY2018Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	159000	USD
CY2017Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2018Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	48000	USD
CY2017Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	44000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1143000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	956000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	76000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2172000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8088000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5916000	USD
CY2018Q3	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	3000	USD
CY2017Q3	ibio	Unpaid Intangible Assets Included In Accounts Payable UnpaidIntangibleAssetsIncludedInAccountsPayable	7000	USD
CY2018Q3	ibio	Capital Expenditure Incurred For Intangible Assets Paid CapitalExpenditureIncurredForIntangibleAssetsPaid	2000	USD
CY2017Q3	ibio	Capital Expenditure Incurred For Intangible Assets Paid CapitalExpenditureIncurredForIntangibleAssetsPaid	11000	USD
CY2018Q3	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	0	USD
CY2017Q3	ibio	Unpaid Fixed Assets Included In Accounts Payable UnpaidFixedAssetsIncludedInAccountsPayable	9000	USD
CY2018Q3	ibio	Capital Expenditures Incurred Payments Made CapitalExpendituresIncurredPaymentsMade	85000	USD
CY2017Q3	ibio	Capital Expenditures Incurred Payments Made CapitalExpendituresIncurredPaymentsMade	87000	USD
CY2018Q3	us-gaap	Interest Paid Net InterestPaidNet	477000	USD
CY2017Q3	us-gaap	Interest Paid Net InterestPaidNet	481000	USD
CY2018Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4350000	shares
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1000
CY2018Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	7000000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	2666666	shares
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1500000	shares
CY2018Q3	ibio	Sub Lease Expiration Period SubLeaseExpirationPeriod	P34Y
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2018Q3	ibio	Registration Common Stock RegistrationCommonStock	1500000	USD
CY2017Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2250000	shares
CY2017Q4	ibio	Offering Price To New Investors OfferingPriceToNewInvestors	0.07	pure
CY2017Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.00
CY2017Q4	ibio	Offering Price To Existing Investors OfferingPriceToExistingInvestors	0.035	pure
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.90
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16000000	USD
CY2018Q2	ibio	Offering Price To New Investors OfferingPriceToNewInvestors	0.07	pure
CY2018Q2	ibio	Offering Price To Existing Investors OfferingPriceToExistingInvestors	0.035	pure
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-4398000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-3826000	USD
CY2017Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4500000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2100000	USD
CY2018Q3	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	476000	USD
CY2017Q3	us-gaap	Capital Leases Income Statement Interest Expense CapitalLeasesIncomeStatementInterestExpense	480000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	2100000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	2100000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	2100000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	2100000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	2100000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	55650000	USD
CY2018Q3	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	66150000	USD
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2018Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	6300	shares
CY2018Q2	us-gaap	Share Price SharePrice	0.90
CY2018Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	807	shares
CY2018Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	896666	shares
CY2018Q3	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	66000	USD
CY2017Q3	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	66000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4464000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3892000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17894000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9185000	shares
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13895000	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1360000	shares
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	205000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1364583	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.01
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M24D
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	833	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.00
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1363750	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.02
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y7M6D
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1242572	shares
CY2018Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1363750	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.76
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y2M12D
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2018Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P4Y7M6D
CY2018Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	12.02
CY2018Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1242572	shares
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	571000	USD
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	773000	USD
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	304000	USD
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.85
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2018Q3	ibio	Long Term Purchase Commitment Expire Date LongTermPurchaseCommitmentExpireDate	2015-12-31
CY2018Q3	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	200000	USD
CY2018Q3	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2017Q3	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05	pure
CY2018Q3	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	33000	USD
CY2017Q3	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	0	USD
CY2018Q3	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
CY2018Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	27000	USD
CY2017Q3	ibio	Revenue From Intersegment RevenueFromIntersegment	0	USD
CY2017Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	14000	USD
CY2017Q3	us-gaap	Assets Assets	33433000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25268000	USD
CY2017Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1757000	USD
CY2018Q3	us-gaap	Share Price SharePrice	0.78
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4200000	USD
CY2018Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	185000	USD
CY2018Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	189000	USD
CY2018Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	812000	USD
CY2018Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	789000	USD
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	275000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18336792	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16040126	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18336792	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16040126	shares
CY2018Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	259000	USD
CY2017Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	176000	USD
CY2018Q3	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	261000	USD
CY2017Q3	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	206000	USD
CY2018Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	476000	USD
CY2017Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	480000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1350000	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000000	USD
CY2018Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1000	USD
CY2017Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2018Q3	us-gaap	Nature Of Operations NatureOfOperations	<div style="text-align:left;"><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 100%;"><tr><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top; width: 3%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td><td style="border-width: initial; border-bottom-style: none; border-color: initial; border-top-style: none; padding: 0pt 0px; vertical-align: top; width: 97%;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nature of Business</div></div></div></td></tr></table><div style="clear:both;"></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on using our proprietary technologies and production facilities to provide product development and manufacturing services to clients, collaborators and third-party customers as well as developing and commercializing our own product candidates.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows:</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 1in; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">iBio CDMO LLC</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> (“iBio CDMO”) (originally named iBio CMO LLC) – iBio CDMO is a Delaware limited liability company formed on December 16, 2015 as iBio CMO, LLC to develop and manufacture plant-made pharmaceuticals and provide related services to clients. Effective July 1, 2017, iBio CMO changed its name to iBio CDMO. As of December 31, 2015, the Company owned 100% of iBio CDMO. On January 13, 2016, the Company entered into a contract manufacturing joint venture with an affiliate of Eastern Capital Limited (“Eastern”), a stockholder of the Company (the “Eastern Affiliate”). The Eastern Affiliate contributed $15 million in cash for a 30% interest in iBio CDMO. The Company retained a 70% interest in iBio CDMO and contributed a royalty-bearing license which grants iBio CDMO a non-exclusive license to use the Company’s proprietary technologies for research purposes and an exclusive U.S. license for manufacturing purposes. The Company retained the exclusive right to grant product licenses to those who wish to sell or distribute products made using the Company’s technologies.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate, pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate in exchange for one share of the Company’s iBio CMO Preferred Tracking Stock, par value $0.001 per share. After giving effect to the transaction, the Company owns 99.99% of iBio CDMO. See Note 9 for a further discussion.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">iBio CDMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a 139,000-square foot Class A life sciences building located on land owned by the Texas A&M system, designed and equipped for plant-made manufacture of biopharmaceuticals. The Second Eastern Affiliate granted iBio CDMO a 34-year capital lease for the facility as well as certain equipment (see Note 8). iBio CDMO commenced commercial operations in January 2016. iBio CDMO expects to operate on the basis of three parallel lines of business: (1) Development and manufacturing of third-party products; (2) Development and production of iBio’s proprietary product(s) for treatment of fibrotic diseases and/or other proprietary iBio products; and (3) Commercial technology transfer services including facility design, as needed.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">iBIO DO BRASIL BIOFARMACÊUTICA LTDA</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> (“iBio Brazil”) – iBio Brazil is a subsidiary organized in Brazil in which the Company has a 99% interest. iBio Brazil was formed to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with Fundacao Oswaldo Cruz/Fiocruz (“Fiocruz”) beyond the Yellow Fever Vaccine program (see Note 7) and development of additional products with private sector participants for the Brazilian market. iBio Brazil commenced operations during the first quarter of the fiscal year ended June 30, 2015.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; text-align: justify;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">iBio Manufacturing LLC</div></div><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> (“iBio Manufacturing”) – iBio Manufacturing, a wholly-owned subsidiary, is a Delaware limited liability company formed in November 2015. iBio Manufacturing has not commenced any activities to date. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.90
CY2018Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2900000	USD
CY2018Q3	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q3	ibio	Revenues From Grants RevenuesFromGrants	0	USD
CY2017Q3	ibio	Revenues From Grants RevenuesFromGrants	44000000	USD
CY2018Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2018Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5601000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5584000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4047000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3964000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1554000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1620000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2018Q3	dei	Entity Listing Description EntityListingDescription	On June 6, 2018, the Company received notification from the NYSE American that it is not in compliance with the continued listing standards as set forth in Section 1003(a)(iii) of the NYSE American’s Company Guide that, which applies if a listed company has stockholders’ equity of less than $6,000,000 and has sustained losses from continuing losses and/or net losses in its five most recent fiscal years.
CY2018Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On April 23, 2018, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to effect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio to be determined by the Company's Board of Directors in a range not less than one-for-two (1:2) and not greater than one-for-ten (1:10).
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1361939	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12.03
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y7M6D
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriodDescription	Plan was amended to increase the number of shares reserved for awards under the Plan from 1 million to 1.5 million.
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.90
CY2018Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On June 8, 2018, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a one-for-ten (1:10) reverse stock split of the shares of the Company’s common stock, either issued and outstanding or held by the Company as treasury stock, effective as of 4:10 p.m. (Eastern Time), June 8, 2018. The Company’s common stock began trading on a reverse split adjusted basis on the Exchange when the market opened Monday, June 11, 2018.
CY2018Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On May 23, 2018, the Company's board of directors approved the implementation of a reverse stock split at a ratio of one-for-ten (1:10) shares of the Company's Common Stock. As a result of the reverse stock split, every ten (10) shares of the Company's Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Company's common stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares.
CY2018Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12500000	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120000	shares
CY2017Q4	ibio	Underwriting Discounts Commissions And Other Offering Expenses UnderwritingDiscountsCommissionsAndOtherOfferingExpenses	311000	USD
CY2018Q3	ibio	Underwriting Discounts Commissions And Other Offering Expenses UnderwritingDiscountsCommissionsAndOtherOfferingExpenses	854000	USD
CY2018Q3	ibio	Underwriting Discounts Commissions And Other Offering Expenses UnderwritingDiscountsCommissionsAndOtherOfferingExpenses	159000	USD
CY2018Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	796666	shares
CY2017Q4	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1.05	USD
CY2017Q4	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	3500000	USD
CY2018Q2	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1.093	USD
CY2018Q3	ibio	Capital Lease Obligation Description CapitalLeaseObligationDescription	the base rent, iBio CDMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CDMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CDMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to approximately $87,000 and $17,000 for the three months ended September 30, 2018 and 2017, respectively
CY2018Q3	dei	Document Type DocumentType	10-Q
CY2018Q3	dei	Amendment Flag AmendmentFlag	false
CY2018Q3	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
CY2018Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2018Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q3	dei	Entity Registrant Name EntityRegistrantName	iBio, Inc.
CY2018Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001420720
CY2018Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2018Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18636792	shares
CY2018Q3	dei	Trading Symbol TradingSymbol	IBIO
CY2018Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28612000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	28424000	USD
CY2018Q3	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	3333000	USD
CY2018Q2	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	3027000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	298000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets	245000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3631000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3272000	USD

Files In Submission

Name	View Source	Status
0001144204-18-059349-index-headers.html	Edgar Link	pending
0001144204-18-059349-index.html	Edgar Link	pending
0001144204-18-059349.txt	Edgar Link	pending
0001144204-18-059349-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ibio-20180930.xml	Edgar Link	completed
ibio-20180930.xsd	Edgar Link	pending
ibio-20180930_cal.xml	Edgar Link	unprocessable
ibio-20180930_def.xml	Edgar Link	unprocessable
ibio-20180930_lab.xml	Edgar Link	unprocessable
ibio-20180930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv506627_10q.htm	Edgar Link	pending
tv506627_ex31-1.htm	Edgar Link	pending
tv506627_ex31-2.htm	Edgar Link	pending
tv506627_ex32-1.htm	Edgar Link	pending
tv506627_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IBIO
iBio, Inc. Stock $ibio

2018 Q4 Form 10-Q Financial Statement

#000114420418059349 Filed on November 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO iBio, Inc. Stock $ibio

2018 Q4 Form 10-Q Financial Statement

#000114420418059349 Filed on November 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IBIO
iBio, Inc. Stock $ibio